

No. 18-817

---

---

IN THE  
Supreme Court of the United States

HIKMA PHARMACEUTICALS USA INC., AND WEST-WARD  
PHARMACEUTICALS INTERNATIONAL LTD., N/K/A HIKMA  
PHARMACEUTICALS INTERNATIONAL LTD.,  
*Petitioners,*

v.

VANDA PHARMACEUTICALS INC.,  
*Respondent.*

ON PETITION FOR A WRIT OF CERTIORARI TO THE  
UNITED STATES COURT OF APPEALS  
FOR THE FEDERAL CIRCUIT

**BRIEF IN OPPOSITION**

---

Nicholas Groombridge  
*Counsel of Record*  
Eric Alan Stone  
Kira Alexis Davis  
Josephine Young  
Daniel J. Klein

PAUL, WEISS, RIFKIND, WHARTON  
& GARRISON LLP  
1285 Avenue of the Americas  
New York, NY 10019  
(212) 373-3212  
ngroombridge@paulweiss.com

FEBRUARY 12, 2019 *Counsel for Respondent*

---

---

## QUESTION PRESENTED

Hikma's Petition wrongly asserts that the Federal Circuit declared all method-of-treatment claims to be "automatically" patent-eligible under Section 101, and asks this Court to decide:

Whether patents that claim a method of medically treating a patient automatically satisfy Section 101 of the Patent Act, even if they apply a natural law using only routine and conventional steps.

That Question is not presented by the decision below or any other decision.

## **PARTIES TO THE PROCEEDINGS**

The caption identifies all parties. Petitioners are Hikma Pharmaceuticals USA Inc., and West-Ward Pharmaceuticals International Ltd., N/K/A Hikma Pharmaceuticals International Ltd. (together, “Hikma”). The Respondent is Vanda Pharmaceuticals Inc.

## CORPORATE DISCLOSURE STATEMENT

Vanda is publicly traded on the NASDAQ (symbol: VNDA). No publicly traded entity owns more than 10% of Vanda's stock.

**TABLE OF CONTENTS**

	<b>Page</b>
QUESTION PRESENTED .....	i
PARTIES TO THE PROCEEDINGS .....	ii
CORPORATE DISCLOSURE STATEMENT .....	iii
BRIEF IN OPPOSITION .....	1
STATEMENT OF THE CASE .....	4
A.    Iloperidone and QTc Prolongation.....	4
B.    Vanda’s Invention and FDA Approval .....	4
C.    The District Court Proceedings .....	7
D.    The Federal Circuit Decision.....	8
REASONS FOR DENYING THE PETITION .....	9
I. THE FEDERAL CIRCUIT FAITHFULLY APPLIED—AND ANNOUNCED NO CATEGORICAL EXEMPTION FROM—THIS COURT’S SECTION 101 PRECEDENTS.....	12
II. THE ’610 PATENT CLAIMS ARE PATENT- ELIGIBLE UNDER THIS COURT’S PRECEDENT .....	22

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.